Recent studies have shown the potential of MEK inhibitors for use in immune-sensitization by up-regulation of tumor antigen expression and presentation [74,75], and through production of IL-8 and vascular endothelial growth factor (VEGF), enhancing recruitment of immune cell to the tumor site [76]. The gene discussed is VEGFA; the disease is neoplasm.